Table 1.

Dual action platinum(IV) prodrugs with NSAIDs as axial ligand(s). DU145—androgen independent human prostate adenocarcinoma cells; HNSCC—Head and neck squamous cell carcinoma; MDA-MB-231—triple negative human breast adenocarcinoma; HCT-116—human colon carcinoma; BEL7404—human hepatoma cell line; A2780—human ovarian carcinoma; MCF-7—human breast adenocarcinoma; CT-26—murine colorectal carcinoma.

Compound	Pt(II) Drug	NSAID	R (Second Axial Position)	IC50 (Tumor Cell Type)	In Vivo Studies (Tumor, Dose, Tumor Growth Suppression, Day of Treatment)	Reference
1	Cisplatin	Aspirin	Hydroxyl	8 ± 3 (DU145)	-	[20]
2	Cisplatin	Indometacin	Indometacin	0.69 (1483 HNSCC)	-	[21]
3	Cisplatin	Ibuprofen	Ibuprofen	0.045 (1483 HNSCC)
4	Oxaliplatin	Indometacin	Indometacin	0.55 (MDA-MB-231)	-	[22]
5	Oxaliplatin	Ibuprofen	Ibuprofen	0.33 (MDA-MB-231)
6	Kiteplatin	Ibuprofen	Ibuprofen	0.26 ± 0.03 (HCT116)	-	[23]
7	Cisplatin	Flurbiprofen	Flurbiprofen	1.4 ± 1.1 (BEL7404)	-	[24]
8	Cisplatin	Ketoprofen	Acetyl	0.063 ± 0.033 (A2780)	-	[25]
9	Cisplatin	Naproxen	Acetyl	0.045 ± 0.033 (A2780)
10	Cisplatin	Naproxen	Hydroxyl	10.40 ± 0.79 (MCF-7)	-	[26]
11	Carboplatin	Naproxen	Hydroxyl	9.12 ± 0.63 (MCF-7)
12	Oxaliplatin	Naproxen	Hydroxyl	9.47 ± 0.75 (MCF-7)
13	Cisplatin	Naproxen	Benzoic acid	3.92 ± 0.42 (MCF-7)
14	Cisplatin	Naproxen	Succinic acid	7.65 ± 0.84 (MCF-7)
15	Cisplatin	Naproxen	Glutaric acid	8.73 ± 0.89 (MCF-7)
16	Cisplatin	Naproxen	Cl	0.2 ± 0.1 (CT-26)	17: CT-26 4 mg/kg 82.5% 15 days	[27]
17	Oxaliplatin	Naproxen	Cl	2.9 ± 0.7 (CT-26)
18	Carboplatin	Naproxen	Cl	26.1 ± 8.6 (CT-26)
19	Oxaliplatin	Naproxen	Naproxen	8.2 ± 0.6 (CT-26)
20	Carboplatin	Naproxen	Naproxen	27.3 ± 5.7 (A549)
21	Cisplatin	Naproxen	Naproxen	0.16 ± 0.01 (MDA-MB-231)	21: MDA-MB-231; 1.5 mg/kg 92.8% 15 days	[28]
10	Cisplatin	Naproxen	Hydroxyl	0.40 ± 0.10 (MCF-7)
22	Cisplatin	Etodolac	Etodolac	0.17 ± 0.04 (MCF-7)	22: MCF-7; 3 mg/kg 15 days, 60.6%	[29]
23	Cisplatin	Carprofen	Carprofen	0.95 ± 0.04 (MCF-7)
24	Cisplatin	Sulindac	Sulindac	2.68 ± 1.09 (MCF-7)